PortalPublikationenTherapy of gastric mucosa associated lymphoid tissue lymphom...

Therapy of gastric mucosa associated lymphoid tissue lymphoma

Standard

Therapy of gastric mucosa associated lymphoid tissue lymphoma. / Morgner, Andrea; Schmelz, Renate; Thiede, Christian; Stolte, Manfred; Miehlke, Stephan.

in: WORLD J GASTROENTERO, Jahrgang 13, Nr. 26, 14.07.2007, S. 3554-66.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Morgner, A, Schmelz, R, Thiede, C, Stolte, M & Miehlke, S 2007, 'Therapy of gastric mucosa associated lymphoid tissue lymphoma', WORLD J GASTROENTERO, Jg. 13, Nr. 26, S. 3554-66.

APA

Morgner, A., Schmelz, R., Thiede, C., Stolte, M., & Miehlke, S. (2007). Therapy of gastric mucosa associated lymphoid tissue lymphoma. WORLD J GASTROENTERO, 13(26), 3554-66.

Vancouver

Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. WORLD J GASTROENTERO. 2007 Jul 14;13(26):3554-66.

Bibtex

@article{9f037fe994374d88b3eca36229989c99,
title = "Therapy of gastric mucosa associated lymphoid tissue lymphoma",
abstract = "Gastric mucosa associated lymphoid tissue (MALT) lymphoma has recently been incorporated into the World Health Organization (WHO) lymphoma classification, termed as extranodal marginal zone B-cell lymphoma of MALT-type. In about 90% of cases this lymphoma is associated with H pylori infection which has been clearly shown to play a causative role in lymphomagenesis. Although much knowledge has been gained in defining the clinical features, natural history, pathology, and molecular genetics of the disease in the last decade, the optimal treatment approach for gastric MALT lymphomas, especially locally advanced cases, is still evolving. In this review we focus on data for the therapeutic, stage dependent management of gastric MALT lymphoma. Hence, the role of eradication therapy, surgery, chemotherapy and radiotherapy is critically analyzed. Based on these data, we suggest a therapeutic algorithm that might help to better stratify patients for optimal treatment success.",
keywords = "Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Combined Modality Therapy, Helicobacter Infections, Helicobacter pylori, Humans, Lymphoma, B-Cell, Marginal Zone, Neoplasm Staging, Organoplatinum Compounds, Radiotherapy, Rituximab, Stomach Neoplasms, Journal Article, Review",
author = "Andrea Morgner and Renate Schmelz and Christian Thiede and Manfred Stolte and Stephan Miehlke",
year = "2007",
month = jul,
day = "14",
language = "English",
volume = "13",
pages = "3554--66",
journal = "WORLD J GASTROENTERO",
issn = "1007-9327",
publisher = "WJG Press",
number = "26",

}

RIS

TY - JOUR

T1 - Therapy of gastric mucosa associated lymphoid tissue lymphoma

AU - Morgner, Andrea

AU - Schmelz, Renate

AU - Thiede, Christian

AU - Stolte, Manfred

AU - Miehlke, Stephan

PY - 2007/7/14

Y1 - 2007/7/14

N2 - Gastric mucosa associated lymphoid tissue (MALT) lymphoma has recently been incorporated into the World Health Organization (WHO) lymphoma classification, termed as extranodal marginal zone B-cell lymphoma of MALT-type. In about 90% of cases this lymphoma is associated with H pylori infection which has been clearly shown to play a causative role in lymphomagenesis. Although much knowledge has been gained in defining the clinical features, natural history, pathology, and molecular genetics of the disease in the last decade, the optimal treatment approach for gastric MALT lymphomas, especially locally advanced cases, is still evolving. In this review we focus on data for the therapeutic, stage dependent management of gastric MALT lymphoma. Hence, the role of eradication therapy, surgery, chemotherapy and radiotherapy is critically analyzed. Based on these data, we suggest a therapeutic algorithm that might help to better stratify patients for optimal treatment success.

AB - Gastric mucosa associated lymphoid tissue (MALT) lymphoma has recently been incorporated into the World Health Organization (WHO) lymphoma classification, termed as extranodal marginal zone B-cell lymphoma of MALT-type. In about 90% of cases this lymphoma is associated with H pylori infection which has been clearly shown to play a causative role in lymphomagenesis. Although much knowledge has been gained in defining the clinical features, natural history, pathology, and molecular genetics of the disease in the last decade, the optimal treatment approach for gastric MALT lymphomas, especially locally advanced cases, is still evolving. In this review we focus on data for the therapeutic, stage dependent management of gastric MALT lymphoma. Hence, the role of eradication therapy, surgery, chemotherapy and radiotherapy is critically analyzed. Based on these data, we suggest a therapeutic algorithm that might help to better stratify patients for optimal treatment success.

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Agents

KW - Combined Modality Therapy

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Lymphoma, B-Cell, Marginal Zone

KW - Neoplasm Staging

KW - Organoplatinum Compounds

KW - Radiotherapy

KW - Rituximab

KW - Stomach Neoplasms

KW - Journal Article

KW - Review

M3 - SCORING: Journal article

C2 - 17659705

VL - 13

SP - 3554

EP - 3566

JO - WORLD J GASTROENTERO

JF - WORLD J GASTROENTERO

SN - 1007-9327

IS - 26

ER -